Skip to content
Psychiatrist.com Logo
  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Advanced Search

Menu

  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Sign in Subscribe

Clinical Topics

View All
  • Addiction
  • ADHD
  • Alzheimer’s Disease
  • Anxiety
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Neurology
  • OCD
  • Psychopharmacology
  • PTSD and Trauma
  • Schizophrenia/Schizoaffective Disorders
  • Sleep
  • Tardive Dyskinesia
  • View All

Collections

View All
  • Academic Highlights
  • Auvelity: Information from Industry
  • Banner Alzheimer’s Institute
  • Clinical & Practical Psychopharmacology
  • Early Career Psychiatrists
  • Focus on Childhood and Adolescent Mental Health
  • Focus on Geriatric Psychiatry
  • Focus on Psychotherapy
  • Focus on Suicide
  • Focus on Psychosis
  • Focus on Women’s Mental Health
  • Rounds in the General Hospital
  • UZEDY: Information from Industry
  • View All
Back to top Open menu arrow
Download PDF Reprints
No sections available

The Primary
Care Companionfor CNS Disorders

Free access
Schizophrenia/Schizoaffective Disorders

Letter to the Editor June 1, 2004

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis

Thomas J. Kim, MD, MPH; H. W. LeBourgeois III, MD

Prim Care Companion J Clin Psychiatry 2004;6(3):136-137

Article Abstract
Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis.

About the Authors

  • Thomas J. Kim, MD, MPH
    View full profile
  • H. W. LeBourgeois III, MD
    View full profile
Download Free PDF

This PDF is free for all visitors!

Related News Articles

New Clues Why Schizophrenia Patients Hear Voices How Social Thinking Shapes Recovery in Early Schizophrenia Weekly Mind Reader: Cognitive Impairments and Schizophrenia

Sponsored

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia
Explore two real-world schizophrenia cases with Roueen Rafeyan, MD and Melissa Vitale, PMHNP as they discuss challenges with medication adherence, transitioning to long-acting injectables (LAIs), and personalizing treatment strategies to improve patient outcomes.

Related JCP Articles

Evaluating the Transfer of Lurasidone Into Human Milk Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder The Superiority of Clozapine Over SGAs in Patients With Treatment-Resistant Schizophrenia

Related PCC Articles

NMS After Clozapine and ECT N-Acetylcysteine for Psychogenic Polydipsia Mosaic Turner Syndrome and Schizophrenia
A journal cover titled The Primary Care Companion for CNS Disorders lists featured articles on depression predictors, medical student reactions, climate change and mental health, and case reports. There is a QR code at the bottom right.

Vol 27 • 2025 • Number 4

Read the Current Issue

Letter to the Editor

Knowledge of ECT for Catatonia

Original Research

Predictors of Depression Response in a Community ECT Clinic

Original Research

Medical Student Reactions to Interviewing Psychiatric Inpatients

Review Article

Climate Change and Mental Health

Rounds in the General Hospital

Management of Functional Neurological Disorder

Rounds in the General Hospital

PTSD Management in Primary Care

View current Issue

Related Articles

JCP
Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?
Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...
Xintong Mu, Hiroyoshi Takeuchi
JCP
Asenapine, Aggression, and Affinity
Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.
Rif S. El-Mallakh
JCP
A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole
Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.
Barbara Mintzes, Alain Braillon, Florian Naudet, et al

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Read the full report
Figure shows a syringe and vials with title on aripiprazole monohydrate LAI use in schizophrenia and a red READ NOW button.

Subscribe to read
more articles

Subscribe
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

ELSEWHERE:

  • ABOUT
  • ADVERTISERS
  • MEDIA RELATIONS
  • REPRINTS & PERMISSIONS
  • CONTACT US
  • CUSTOMER SUPPORT

FOLLOW US:

  • X
  • FACEBOOK
  • INSTAGRAM
  • LINKEDIN
  • SIGN IN

  • JOIN THE EMAIL LIST


SUBSCRIBE NOW
An image of the Psychiatrist.com logo mark
  • Privacy Policy
  • Terms of Use
  • Physicians Postgraduate Press, Inc.
  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • © Copyright 2025 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians
  • Sitemap